Champions Oncology, Inc. (CSBR) research, news, and more from GeoInvesting

Company description

Fri, 03 Jan 2025 17:11:07 GMT

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Research

Tue, 16 Sep 2025 15:37:26 GMT

Champions Oncology, Inc. (NASDAQ:CSBR) ($8.30; $114.4M market cap) announced Q1 2026 results:

Q1 2026 sales of $14.0 million vs. $14.1 million in the prior year
Q1 2026 adjusted EPS: $0.02 vs. $0.14 in the prior year
Cash on hand of $10.3 million with no debt

"It is great to be joining Champions at such an exciting inflection point. Our core services business – the backbone of our company – is strengthening and well positioned for sustained growth. At the same time, we are scaling our emerging data platform, which has already shown encouraging traction with leading biopharma partners. These complementary growth engines give us the opportunity to deepen our scientific impact, deliver innovative solutions to patients and customers, and create durable long-term value for shareholders. In parallel, our Corellia team continues to generate data demonstrating the potential of the compounds in our pipeline. Over the coming quarters, I look forward to working closely with our talented team to sharpen our strategy, invest in key capabilities, and build on Champions' culture of collaboration and scientific excellence." – Rob Brainin, CEO

Earnings call highlights:

“Our data platform is also gaining momentum. Since closing our first licensing deal less than a year ago, we've now generated data sales for three consecutive quarters. By leveraging our uniquely characterized PDX bank, we're creating the most comprehensive and clinically relevant tumor dataset in the industry. As AI and machine learning become increasingly central to drug discovery, we see significant long-term opportunity in this business…

…We definitely feel like this was potentially the low point for the fiscal year in terms of revenue. And we do anticipate that it will expand over the coming quarters.”

Our Quick Take:

As we’ve stated, the only reason we are following CSBR is to monitor the traction in its high margin data licensing business, which still is not at a level to offset stagnant growth of its legacy business.

Champions Oncology, Inc. provides technology-driven research solutions for drug discovery and development, offering tumor modeling, translational oncology services, and bioinformatics software to pharmaceutical and biotechnology companies.
–

Research

Thu, 24 Jul 2025 15:27:03 GMT

Champions Oncology, Inc. (NASDAQ:CSBR) ($7.75; $107.1M market cap) announced fourth quarter and full year 2025 results:

Q4 sales of $12.3 million vs $14.0 million in the prior year but ahead of analyst estimates of $12.0 million
Q4 adjusted loss of $0.07 vs adjusted EPS of $0.07 but ahead of analyst estimates of a loss of $0.20
Full year sales of $56.9 million vs $50.2 million in the prior year
Full year adjusted EPS of $0.53 vs adjusted loss of $0.29

"This past year was pivotal for the Company, as we returned to growth and profitability, launched a high-margin data business and laid the foundation for long-term value creation". Added Morris, "With a strong pipeline heading into fiscal 2026, we're confident in our ability to drive continued revenue growth and further accelerate the monetization of our data offering."

David Miller, CFO of Champions added, "Our financial turnaround in fiscal 2025 was driven by disciplined execution and operational efficiency. We delivered record adjusted EBITDA, and strengthened our balance sheet, all while investing in scalable growth. We believe we're well positioned to build on this momentum in fiscal 2026."

Our Quick Take:

If we take earnings call management comments literally, it appears that the new data licensing business that we’re excited about will not be a huge growth driver in the near term. From the conference call:

“So, we really still feel like we're at the right place at the right time. We are – so, the pipeline is growing. So, some of the licensing deals will be smaller, and those will happen sooner. And some of the larger licensing deals take more time. But I think that it's reasonable to expect that our licensing revenue will be somewhat in the same range for the next year or so, and then I think it's going to grow from there, so.”

We’re not huge fans of the legacy business growth outlook, so this is a little bit of a buzzkill. Hopefully, the new CEO can accelerate the growth path for growth in the licensing business, so that it becomes a consistently large part of the business, as opposed to lumpy revenue here and there. Interestingly, the company did land some smaller licensing deals during the quarter, around $200,000, but way less than the $5 million deal they announced in Q3.

It’s tough to say how investors will react to all this. A few days ago, the company appointed a new CEO whose compensation package is tied to the growth in the data licensing business, where some bonuses kick in if he lands $15 million a year in contracts. We’re struggling with how to value this currently inconsistent revenue stream.

We will continue to monitor for further developments in the data licenses business plan.

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States

PodClips

Mon, 05 May 2025 13:10:39 GMT

CSBR Stock Decline: Regulatory and Business Model Shifts

In his most recent PodClip, Maj discusses the recent sharp drop in $CSBR, from its 52-week high of $11.99 to it current price of $5.80, possibly attributing the decline to two main factors: Investor overreaction to the potential impact of the FDA’s initiative (FDA 2.0) promoting alternatives to animal testing in biotech research, and the absence of additional data licensing contracts, following a major $5 million contract.

The company’s legacy business relies heavily on mice testing for cancer research.

What some investors may not realize is that this initiative was originally passed in December 2022, while some framework around the initiative was put in place in April 2024, which may be bringing some current attention to the initiative.

There is also a 3 to 5 year phase in process of this initiative and to be clear, the initiative is not regulating that biotech companies cannot test on animals, it’s just encouraging them to look at more modern testing tools and processes, such as using AI.

Actually, Maj discusses how the company's 40 years of rich data set could potentially benefit from the 2.0 initiative as the use of AI is being promoted in biotechnology. This could possibly accelerate contract wins in the company's data licensing business and why pharma companies have been expressing interest in acquiring the company’s data.

However, there are caveats that Maj discusses, regarding this new revenue stream.

In the end, the CSBR play has always been on the new data licensing revenue stream and its ability to secure additional contracts. It was never about the legacy business, which Maj is not a big fan of.

Regardless, the stock faces volatility and uncertainty, especially with the lack of new contracts.

Maj suggests that investors should focus on the long-term opportunity of the data licensing model, adapting their portfolio positions based on evolving potential clarity from CSBR’s management in the upcoming earnings call around securing additional contracts, and the near term impact, if any, of FDA 2.0.

---

Research

Wed, 12 Mar 2025 13:59:35 GMT

Champions Oncology, Inc. (NASDAQ:CSBR) ($9.79; $134.1M market cap) announced third quarter 2025 results:

On December 30, 2024 we added the stock to our select coverage Universe at $8.35

Maj was on the related earnings conference call to ask some questions on the new business data license model (quotes related to the model are referenced at the bottom of this note).

Sales of $17.0 million vs $12.0 million in the prior year
Non-GAAP EPS of $0.33 vs loss of $0.16 in the prior year

"Our third quarter was transformational, marked by our first major data licensing agreement-an important milestone toward monetizing our proprietary data platform." Added Morris, "despite ongoing funding constraints in the pharma and biotech sectors, we continue to drive strong performance in our core services business.

We delivered record breaking financial results this quarter, with revenue surpassing $17.0 million and adjusted EBITDA reaching $5.2 million. While we anticipate some fluctuations in quarterly revenue, our strategic cost realignment positions us for sustained long-term profitability."

The company’s strong quarter results were fueled by the $5 million contract from the new data license revenue stream which we highlighted in our January 23 2025 research note. We feel investors are uncertain if the data license revenue is more one-time in nature or a new high margin revenue stream business. Management has stated that they have seen increased demand and eluded to similar deals in the pipeline but also remains cautious about providing any outlook given the infancy of this new model.

Here our some quotes from the conference call on the data license model:

Bullish side:

“Q3 marked a transformative quarter for Champions Oncology, underscored by our record revenue of $17 million and the successful closure of our inaugural data deal. Our core services business remains at the forefront, driven by our industry leading PDX bank and its precisely characterized multiomics data, which has become the foundation for the pharmacology studies that have been used broadly by the biopharma industry.”

“With the rise of AI, which can extract deeper insights from the biological data, the demand for our dataset has notably increased in both breadth and depth. Recognizing this shift, we are actively exploring ways to extract greater value from this data.”

In direct response to one of Maj’s questions, management stated:

“And right now, we're -- so we're excited about the first deal, which is proof of concept and we have a couple of others in the pipeline.”

Caution:

“I must caution that while we are excited about the initial validation of our strategy and continue to engage with other potential customers to build our opportunity pipeline, it remains premature to forecast the number of deals, their average size or the frequency with which they will occur. Consequently, we are not yet in a position to project the data revenue contribution to our overall results or its impact on our bottom line.”

The main reason/key takeaway on why we believe the company will secure more deals like this in the near future stems from management's remarks in the Q2 conference call transcript, where they mentioned that customers are proactively approaching them about licensing the data.

From the Q3 conference call:

“You have to remember, we work with between 400 and 500 of the pharma and biotech companies. So we work with a large number of the biopharma companies within oncology. So we're fairly well known and we work with a lot of them.”

One last takeaway is that the revenue from these license deals is basically pure profit and that the company is also exploring adding recurring revenue deals in this model. If the company can secure about three or four of these kinds of deals per year, we think the stock should trade at a materially higher price in the future, and at a premium valuation.

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States

Research

Thu, 23 Jan 2025 17:34:36 GMT

A Note on CSBR In Light Of Nvidia CEO Comments, And Trump New Stargate Initiative

In late December 2024, GeoInvesting contributor MS Microcaps published a report on Champions Oncology, Inc. (NASDAQ:CSBR), “Champions Oncology, Inc. (CSBR) InfoArb Cliff Note: New Contract Tucked Away in SEC Filing Goes Unnoticed”. In a nutshell, companies hire CSBR to do cancer research using CSBR’s live cancer tissue “bank”. Leveraging 40 years of research, as well as AI, the company has shifted focus to monetizing raw PDX data, derived from “mice models of human derived tumors”.

In the article, MS Microcaps highlighted the company’s:

Turnaround and Profitability: CSBR has reversed its recent losses, achieving 3 consecutive quarters of profitability in its core business after streamlining operations, as the project funding environment for its biotech and pharmaceutical customers begins to improve.

Transformative Revenue Stream: Leveraging 40 years of research and AI, the company has shifted focus to monetizing raw data, signing its first $5 million data licensing agreement (with a $3 million option) as a significant new revenue stream—an opportunity that was subtly mentioned in the "Subsequent Events" section of the Q2 SEC filing and may be overlooked by investors, and is classic Information Arbitrage (InfoArb).

Through our public GeoInvesting TwitterX handle, we playfully decided to highlight the process by which information like this can be found on companies like CSBR, releasing this Tweet to the public (as a response to our InfoArb report announcement in December).

Of course, there are multiple ways in which InfoArb can be found, but we just wanted to point out how important it is to follow a process and keep trying!

It turns out that CSBR keeps performing, now up 42.3% over the report price of $7.51.

Further validating the potential of the company to take advantage of the AI for cancer research/studies, we wanted to point out a small clip in which the CEO of Nvidia Corporation (NASDAQ:NVDA), Jensen Huang, was the Keynote Speaker at CES 2025.

He explained that Nvidia's AI-driven Virtual Lab leverages advanced analytics to accelerate drug discovery by screening billions of compounds efficiently. Built on the NVIDIA Metropolis blueprint, it utilizes tools like Nvidia Cosmos, Vision Language Models, Llama Nematron, LLMS, and Nemo Retriever. These AI agents analyze massive datasets, including billions of camera feeds, to provide actionable insights.

Finally, even more encouraging is the launching of the Stargate initiative, announced alongside President Trump, a groundbreaking multi billion project aiming to build robust AI infrastructure, including nationwide data centers, with plans to expand the investment to $500 billion. By leveraging advanced technologies and partnerships, the project could revolutionize cancer research by streamlining digital health records and enabling the development of customized vaccines, accelerating precision medicine advancements.

If you missed the MS Microcaps’ report on CSBR, you can find it here.

Research

Mon, 30 Dec 2024 17:04:16 GMT

One of our missions going into 2025 will be to increase our focus on finding information arbitrage opportunities in the value investing microcap universe.

So, we thought it to be a good idea to publish a tweet thread last Friday to get everybody ready for our information arbitrage mission for the new year.

Within the tweet thread, we hinted at a new information arbitrage set up we found.

We just wanted to let you know that we were talking about$ Champions Oncology, Inc. (NASDAQ:CSBR). Champions Oncology, Inc. engages in the development of technology solutions to personalize the development and use of oncology drugs in the United States. Recall that a few days earlier, we published an Information Arbitrage Cliff Note on the company, contributed by MS Microcaps, which can be found there.

After having spoken with management on Friday, we have made the decision to add CSBR to our Select Coverage Universe Model Portfolio.

We’re baffled that the market is so inefficient, in that it still provides us with these opportunities, due to microcaps being so ignored. As investors chase pump and dumps and short-term “Field of Dreams” strategies, they just forget about these boring companies that are focused on the long-term.

The irony of all this is that if investors would look hard enough and just do a little research, as opposed to looking for a free handout from Twitter or some YouTube video, they would understand that these quality companies provide many short term investing opportunities via an information arbitrage strategy.

By the way, the remainder of the Tweets covered some case studies to reinforce our process for finding under-the-radar opportunities born out of InfoArb discoveries, if you want to check it out.

We think and hope your understanding of this is part of the reason you have subscribed to GeoInvesting.

—

Research

Tue, 24 Dec 2024 14:27:34 GMT

Cliff Note on CSBR, Contributed by MS Microcaps

"...

We have found a clear case of information arbitrage that does not seem to be shared anywhere online: Information on a new contract, tucked away in an SEC filing.

We assume the company could triple its EPS with this new high margin contract, when compared to what it just reported in its most recent quarter. While it’s still early, we expect more contracts from this new product line will materialize.

We believe management will be “forced” to PR the contract at some point before its next quarterly report, due in March.

Themes:

New High Margin Data Licensing Revenue - Core Business Stabilizing - Inflection To Profits - Information Arbitrage (SEC filings and earnings call transcripts)

..."

See Full Cliff Note Here

Reasons For Tracking

Mon, 17 Jun 2013 04:00:00 GMT

Champions Biotechnology, Inc. (BB:CSBR) ($0.68) - We don’t really play in the biotech field that much, but when we come across a company that has been consistently growing revenue and/or is profitable, we dig further. We particularly like companies that offer services to other biotech firms - CSBR is one of these instances. The company is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs, and uses this technology, in conjunction with related services, to offer solutions for two customer groups:

A: Its POS business offers physicians and patients information to help guide the development of personalized treatment plans by utilizing its technology platform to empirically test the response of a patient’s tumor to multiple oncology drugs or drug combinations. In addition to its core product, the company also offers related personalized oncology services to customers, including personalized tumor panels designed to provide access to world-renowned oncologists with expertise in particular tumor types who can offer useful insight into possible treatments.

B: Its TOS business utilizes a technology platform to assist pharmaceutical and biotechnology companies with the drug development process. The company provides studies that predict the efficacy of experimental oncology drugs or approved drugs as stand-alone therapies or in combination with other drugs. The studies can be used to determine which types of cancer, if any, are inhibited by, differentially sensitive, or resistant to a drug or drug combination.

In a nutshell, the company helps biotech firms deliver their products quicker to the market and helps cancer patients determine what therapies are best for them. There is no doubt that cancer is a growing industry. CSBR is clearly benefiting from this trend as show by its 2008-2013 revenues:

2008 – $1.4 million
2009 – $3.71 million
2010 – $4.893 million
2011 – $6.882 million
2012 – $7.149 million
2013 – $8.3 million

Even though the company has grown top-line revenue, it is still losing money and quarterly sales have been lumpy. CSBR has dilutive securities of:

3 million warrants at an average exercise price $0.70.

We will look to interview management for more color on the company.